Akebia Therapeutics (AKBA) vs Nature's Sunshine Products (NATR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nature's Sunshine Products (NATR) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 16.2% versus a loss of 71.4%. Over five years, NATR leads with a -18.2% price change compared with -71.4% for AKBA. Akebia Therapeutics is the larger company by market cap ($228.1 million vs $221.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | NATR |
|---|---|---|
| Share price | $0.8233 | $12.58 |
| Market cap | $228.14M | $221.35M |
| 1-day change | +1.04% | +0.08% |
| YTD return | -49.39% | -41.75% |
| 1-year return | -71.41% | -16.20% |
| 5-year return | -71.41% | -18.22% |
| P/E ratio (TTM) | — | 12.46 |
| Forward P/E | — | 10.23 |
| EPS (TTM) | $-0.12 | $1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $28.14 |
| 52-week low | $0.805 | $12.31 |
| Distance from 52-week high | -74.27% | -55.29% |
| Analyst consensus | none | none |
| Avg. price target upside | +376.13% | +142.45% |
| Average volume | 6.18M | 160.23K |
| Shares outstanding | 277.11M | 17.60M |
| Employees | 194 | 806 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NATR has outperformed AKBA by 55.2 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
AKBA vs NATR FAQ
Which is bigger, Akebia Therapeutics or Nature's Sunshine Products?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $228.14M compared with $221.35M for Nature's Sunshine Products (NATR).
Which stock has performed better over the past year, AKBA or NATR?
NATR returned -16.20% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Nature's Sunshine Products in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.